Kazia enters clinical collaboration for metastatic brain cancer

image credit- istock.com

Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with the Alliance for Clinical Trials in Oncology Foundation (Alliance), a US-based cancer research network sponsored by the National Cancer Institute.

Alliance will launch a multi-centre phase II study to investigate the potential use of Kazia's investigational new drug, GDC-0084, alongside several other targeted cancer therapies, in the treatment of brain metastases (cancer that has spread to the brain).

Key Points

• Alliance will initiate an open-label phase II study in patients with brain metastases.
• Depending on the genetic profile of their tumor, patients will be allocated to receive either abemaciclib (Eli Lilly), entrectinib (Genentech), or GDC-0084 (Kazia Therapeutics).
• The trial is expected to recruit up to 150 patients in multiple centers across the US.
• The trial will be led by Alliance, with Kazia providing support including study drug and a financial grant.
• Initiation of this study brings the total number of ongoing clinical trials with GDC-0084 to four, each in different forms of brain cancer.